These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

45 related items for PubMed ID: 19267182

  • 1. Cyclic DGR-peptidomimetic containing a bicyclic reverse turn inducer as a selective alpha(v)beta (5) integrin ligand.
    Trabocchi A, Menchi G, Danieli E, Potenza D, Cini N, Bottoncetti A, Raspanti S, Pupi A, Guarna A.
    Amino Acids; 2010 Jan; 38(1):329-37. PubMed ID: 19267182
    [Abstract] [Full Text] [Related]

  • 2. Cyclic RGD peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands.
    Marchini M, Mingozzi M, Colombo R, Guzzetti I, Belvisi L, Vasile F, Potenza D, Piarulli U, Arosio D, Gennari C.
    Chemistry; 2012 May 14; 18(20):6195-207. PubMed ID: 22517378
    [Abstract] [Full Text] [Related]

  • 3. Mapping the integrin alpha V beta 3-ligand interface by photoaffinity cross-linking.
    Bitan G, Scheibler L, Greenberg Z, Rosenblatt M, Chorev M.
    Biochemistry; 1999 Mar 16; 38(11):3414-20. PubMed ID: 10079087
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the alpha V beta 3 receptor.
    Burgess K, Lim D, Mousa SA.
    J Med Chem; 1996 Oct 25; 39(22):4520-6. PubMed ID: 8893849
    [Abstract] [Full Text] [Related]

  • 5. Cyclic RGD-containing functionalized azabicycloalkane peptides as potent integrin antagonists for tumor targeting.
    Manzoni L, Belvisi L, Arosio D, Civera M, Pilkington-Miksa M, Potenza D, Caprini A, Araldi EM, Monferini E, Mancino M, Podestà F, Scolastico C.
    ChemMedChem; 2009 Apr 25; 4(4):615-32. PubMed ID: 19212960
    [Abstract] [Full Text] [Related]

  • 6. Identification of the principal binding site for RGD-containing ligands in the alpha(V)beta(3) integrin: a photoaffinity cross-linking study.
    Yahalom D, Wittelsberger A, Mierke DF, Rosenblatt M, Alexander JM, Chorev M.
    Biochemistry; 2002 Jul 02; 41(26):8321-31. PubMed ID: 12081480
    [Abstract] [Full Text] [Related]

  • 7. Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.
    Gentilucci L, Cardillo G, Spampinato S, Tolomelli A, Squassabia F, De Marco R, Bedini A, Baiula M, Belvisi L, Civera M.
    J Med Chem; 2010 Jan 14; 53(1):106-18. PubMed ID: 20055426
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and biochemical evaluation of a cyclic RGD oxorhenium complex as new ligand of alphaVbeta3 integrin.
    Aufort M, Gonera M, Chaignon N, Le Clainche L, Dugave C.
    Eur J Med Chem; 2009 Sep 14; 44(9):3394-401. PubMed ID: 19303174
    [Abstract] [Full Text] [Related]

  • 9. Human integrin alphavbeta5: homology modeling and ligand binding.
    Marinelli L, Gottschalk KE, Meyer A, Novellino E, Kessler H.
    J Med Chem; 2004 Aug 12; 47(17):4166-77. PubMed ID: 15293989
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A potent integrin antagonist from a small library of cyclic RGD pentapeptide mimics including benzyl-substituted azabicycloalkane amino acids.
    Arosio D, Belvisi L, Colombo L, Colombo M, Invernizzi D, Manzoni L, Potenza D, Serra M, Castorina M, Pisano C, Scolastico C.
    ChemMedChem; 2008 Oct 12; 3(10):1589-603. PubMed ID: 18770516
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cyclic retro-inverso dipeptides with two aromatic side chains. II. Conformational analysis.
    Yamazaki T, Nunami K, Goodman M.
    Biopolymers; 1991 Nov 12; 31(13):1513-28. PubMed ID: 1814501
    [Abstract] [Full Text] [Related]

  • 16. Divalent cations regulate the organization of integrins alpha v beta 3 and alpha v beta 5 on the cell surface.
    Stuiver I, Ruggeri Z, Smith JW.
    J Cell Physiol; 1996 Sep 12; 168(3):521-31. PubMed ID: 8816906
    [Abstract] [Full Text] [Related]

  • 17. Stereodivergent synthesis of 5-aminopipecolic acids and application in the preparation of a cyclic RGD peptidomimetic as a nanomolar αVβ3 integrin ligand.
    Sernissi L, Ricci L, Scarpi D, Bianchini F, Arosio D, Contini A, Occhiato EG.
    Org Biomol Chem; 2018 May 09; 16(18):3402-3414. PubMed ID: 29675532
    [Abstract] [Full Text] [Related]

  • 18. Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dual αVβ3 and α5β1 integrin ligands.
    Sernissi L, Trabocchi A, Scarpi D, Bianchini F, Occhiato EG.
    Bioorg Med Chem; 2016 Feb 15; 24(4):703-11. PubMed ID: 26753814
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and biological evaluation of dual action cyclo-RGD/SMAC mimetic conjugates targeting α(v)β(3)/α(v)β(5) integrins and IAP proteins.
    Mingozzi M, Manzoni L, Arosio D, Dal Corso A, Manzotti M, Innamorati F, Pignataro L, Lecis D, Delia D, Seneci P, Gennari C.
    Org Biomol Chem; 2014 May 28; 12(20):3288-302. PubMed ID: 24737345
    [Abstract] [Full Text] [Related]

  • 20. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.
    Dechantsreiter MA, Planker E, Mathä B, Lohof E, Hölzemann G, Jonczyk A, Goodman SL, Kessler H.
    J Med Chem; 1999 Aug 12; 42(16):3033-40. PubMed ID: 10447947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.